CDMO Kindeva has announced an agreement with Canadian company Rocket Science Health (RSH) for development of RSH’s “Olfactory Delivery Device,” which is designed for high deposition of drug to the olfactory clefts. Kindeva, which acquired nasal delivery specialist Summit Biosciences in 2024, says that it “is committed to being a leader in the growing intranasal drug delivery space and sees RSH’s technology as a breakthrough innovation.”
Rocket Science Health CEO Kenneth Irving commented, “A personal experience with an unreliable delivery method opened my eyes to the influence of drug devices on health outcomes. That realization led to the founding of Rocket Science Health and nearly a decade of rethinking intranasal delivery. Knowing subregions of the nasal cavity provide access to different organ systems, most notably the CNS via the olfactory clefts, we redesigned the fluidics and user experience to enable precise, targeted delivery. Now, we are ready to bring this technology into clinical trials for advancing dose dependent medicine. Kindeva stood out not only for their track record of supporting drug developers through the trial process, but for their history and shared commitment to making meaningful innovations widely accessible.”
Kindeva Chief Commercial and Operating Officer David Stevens said, “Kindeva’s proven expertise and track record of developing and commercializing novel drug delivery devices makes us the ideal partner to support Rocket Science Health’s new olfactory device. I am incredibly excited to collaborate with the fantastic Rocket team as they look to realize their ambition to create a step change improvement in nasal drug delivery.”
Read the Kindeva press release
